PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to Identify Novel Targets

 PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to Identify Novel Targets

PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to Identify Novel Targets

Shots:

  • The companies collaborated to identify targets for Otsuka’s therapeutics discovery programmes by leveraging PhoreMost’s expertise and next-generation phenotypic screening platform, SITESEEKER
  • Otsuka will validate the novel targets identified in the collaboration as part of its internal development pipeline with an initial focus on gene therapy applications of identified targets
  •  PhoreMost’s SITESEEKER platform deploys protein shape diversity to find functionally active peptides. Based on its PROTEINi technology, it utilizes SITESEEKER to probe the entire proteome in a live cell environment for novel targets linked to any disease

Click here ­to­ read full press release/ article | Ref: PhoreMost | Image: PhoreMost

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post